{"schema_version":"secwatch.filing_event.v1","accession":"0001829126-26-001755","form_type":"8-K","ticker":"NTHI","cik":"0001979414","company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","filed_at":"2026-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.923570+00:00","generated_at":"2026-05-15T23:13:14.283652+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"NeOnc to present Phase 1 dose-escalation data from NEO212 trial on March 4 call","bullets":["Investor conference call scheduled for March 4, 2026 at 9:00 a.m. ET to present initial Phase 1 dose-escalation results from NEO212-01 trial.","Phase 1 portion evaluated oral NEO212 in CNS malignancies; data includes safety, toxicity, PK, and regulatory next steps.","Featured participants: Dr. Henry Friedman (Duke), Dr. Alexandra Miller (NYU Langone), plus NTHI management.","NEO212 is a proprietary bioconjugated temozolomide platform with FDA Fast-Track and IND status for CNS cancers.","No specific data disclosed in this release; full presentation will occur on the call."],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-26-001755","json":"https://secwatch.observer/filing/0001829126-26-001755.json","markdown":"https://secwatch.observer/filing/0001829126-26-001755.md","text":"https://secwatch.observer/filing/0001829126-26-001755.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1979414/000182912626001755/0001829126-26-001755-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1979414/000182912626001755/neonctechnologies_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:13:14.283652+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}